The General Hospital Corporation

The General Hospital Corporation was paid $437.80M by Medicaid between Jan 2018 and Dec 2024, across 1127 billing codes. Its largest line is 99211, Office or other outpatient visit for the evaluation and management of an established patient, minimal severity — 12% of everything it billed.

Compared with peers

Next to other General Acute Care Hospital providers in Massachusetts

Rank by total paid#3 of 66

Median peer was paid$29.11M

This provider vs. median15×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	1,557,798	$63.15M
2019	1,551,617	$63.63M
2020	1,297,624	$59.49M
2021	1,716,642	$78.04M
2022	1,789,081	$87.99M
2023	1,370,774	$53.68M
2024incomplete	978,102	$31.81M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	12%	458,423	392,435	$52.16M
96361	Intravenous infusion, hydration; each additional hour	4.2%	46,839	36,452	$18.36M
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	3.9%	262,907	239,861	$17.09M
99285	Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life	3.9%	83,400	74,255	$17.07M
99284	Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity	3.4%	88,969	80,108	$14.73M
G0378	Hospital observation service, per hour	2.8%	62,234	42,893	$12.14M
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	2.5%	46,357	37,039	$10.86M
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	2.4%	239,487	227,495	$10.38M
99283	Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity	1.9%	58,185	52,851	$8.35M
J9271	Injection, pembrolizumab, 1 mg	1.7%	1,975	1,516	$7.57M
96413	Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance	1.4%	40,357	24,679	$6.28M
G0463	Hospital outpatient clinic visit for assessment and management of a patient	1.3%	296,765	228,223	$5.74M

1115 more codes

90834	Psychotherapy session, about 45 minutes	1.3%	100,269	$5.69M
97110	Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion	1.3%	109,856	$5.53M
77386		1.2%	24,017	$5.17M
43239	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple	1.1%	8,485	$4.99M
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	1.0%	81,937	$4.59M
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour	1.0%	19,370	$4.57M
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	1.0%	3,298	$4.45M
99215	Doctor's office visit, returning patient (complex)	<1%	49,649	$3.98M
74177	Computed tomography, abdomen and pelvis; with contrast material	<1%	30,155	$3.45M
Q5103	Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg	<1%	2,928	$3.16M
45385	Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s)	<1%	4,937	$3.06M
70450	Computed tomography, head or brain; without contrast material	<1%	22,755	$3.04M
99391	Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year)	<1%	35,550	$3.01M
J3380	Injection, vedolizumab, intravenous, 1 mg	<1%	1,280	$3.01M
S9485	Crisis intervention mental health services, per diem	<1%	5,210	$2.99M
99392	Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years)	<1%	42,027	$2.98M
96374	Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance	<1%	46,894	$2.93M
93306	Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete	<1%	19,117	$2.85M
45380	Colonoscopy, flexible; with biopsy, single or multiple	<1%	4,829	$2.82M
96375	Therapeutic injection; each additional sequential IV push	<1%	56,115	$2.75M
96360	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	<1%	19,164	$2.75M
70553	Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences	<1%	8,747	$2.62M
99393	Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years)	<1%	37,698	$2.59M
J9312	Injection, rituximab, 10 mg	<1%	1,087	$2.58M
J1745	Injection, infliximab, excludes biosimilar, 10 mg	<1%	2,808	$2.57M
J2357	Injection, omalizumab, 5 mg	<1%	2,704	$2.54M
96415		<1%	10,837	$2.36M
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	43,179	$2.31M
92507	Treatment of speech, language, voice, communication, and/or auditory processing disorder	<1%	18,244	$2.23M
J2315	Injection, naltrexone, depot form, 1 mg	<1%	2,296	$2.20M
Q9992	Injection, buprenorphine extended-release (sublocade), greater than 100 mg	<1%	1,457	$2.10M
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	15,472	$2.04M
77412		<1%	13,808	$2.01M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	49,778	$1.96M
J9035	Injection, bevacizumab, 10 mg	<1%	1,580	$1.91M
J9355	Injection, trastuzumab, excludes biosimilar, 10 mg	<1%	1,468	$1.89M
99291	Critical care, evaluation and management of the critically ill patient, first 30-74 minutes	<1%	7,096	$1.76M
95810	Polysomnography; sleep staging with 4 or more additional parameters	<1%	2,073	$1.71M
J2350	Injection, ocrelizumab, 1 mg	<1%	129	$1.67M
99394	Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years)	<1%	25,430	$1.65M
70551	Magnetic resonance imaging, brain; without contrast material	<1%	6,213	$1.60M
99203	Doctor's office visit, new patient (routine)	<1%	14,167	$1.59M
77063	Screening digital breast tomosynthesis, bilateral	<1%	27,287	$1.56M
71275	Computed tomographic angiography, chest, with contrast material	<1%	8,138	$1.52M
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	<1%	746	$1.51M
93971		<1%	8,738	$1.44M
71046	Radiologic examination, chest; 2 views	<1%	64,393	$1.42M
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	332,926	$1.41M
J9144	Injection, daratumumab, 10 mg and hyaluronidase-fihj	<1%	1,378	$1.37M
97535	Self-care/home management training, each 15 minutes	<1%	21,183	$1.33M
76856	Ultrasound, pelvic (nonobstetric), real time with image documentation; complete	<1%	12,400	$1.33M
78812		<1%	1,765	$1.32M
J2505	Injection, pegfilgrastim, 6 mg	<1%	978	$1.32M
J3490	Unclassified drugs	<1%	46,913	$1.31M
78452	Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress	<1%	4,506	$1.31M
99282	Emergency department visit for the evaluation and management, low to moderate severity	<1%	9,785	$1.26M
78815	Positron emission tomography (PET) for limited area imaging	<1%	1,693	$1.26M
99201		<1%	11,883	$1.25M
71260	Computed tomography, thorax, diagnostic; with contrast material	<1%	18,090	$1.25M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	42,590	$1.22M
93308		<1%	6,424	$1.19M
76705	Ultrasound, abdominal, real time with image documentation; limited	<1%	12,359	$1.16M
Q5108	Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg	<1%	500	$1.12M
96367		<1%	10,982	$1.08M
76770		<1%	7,426	$1.08M
36430		<1%	5,708	$1.07M
90651		<1%	10,099	$1.06M
99205	Prolong outpt/office vis	<1%	8,052	$1.05M
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	41,291	$1.01M
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	41,077	$1.01M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	63,380	$1.00M
76830	Ultrasound, transvaginal	<1%	11,341	$1.00M
J9263	Injection, oxaliplatin, 0.5 mg	<1%	4,468	$991K
97140	Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage)	<1%	48,958	$982K
76700	Ultrasound, abdominal, real time with image documentation; complete	<1%	7,361	$972K
90832	Psychotherapy session, about 30 minutes	<1%	32,746	$949K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	49,761	$912K
93970		<1%	4,776	$903K
70496		<1%	4,007	$896K
J0185	Injection, aprepitant, 1 mg	<1%	5,121	$885K
77336		<1%	12,485	$847K
43235		<1%	1,479	$832K
74183		<1%	3,239	$824K
71045	Radiologic examination, chest; single view	<1%	30,825	$817K
99395	Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years	<1%	13,108	$811K
J7307	Etonogestrel (contraceptive) implant system, including implant and supplies	<1%	733	$806K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	8,686	$782K
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	<1%	1,004	$781K
84443	Thyroid stimulating hormone (TSH)	<1%	89,350	$766K
G0121	Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk	<1%	1,285	$744K
47562		<1%	301	$741K
97112	Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination	<1%	21,763	$725K
97161		<1%	17,857	$722K
59025	Fetal non-stress test	<1%	2,925	$716K
74176	Computed tomography, abdomen and pelvis; without contrast material	<1%	5,809	$706K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	42,019	$695K
Q0138	Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)	<1%	2,097	$684K
92610		<1%	5,777	$666K
99396	Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years	<1%	13,289	$664K
J0485	Injection, belatacept, 1 mg	<1%	2,813	$661K
77334		<1%	4,371	$656K
76642		<1%	7,770	$654K
97530	Therapeutic activities, direct patient contact, each 15 minutes	<1%	18,704	$653K
45378	Colonoscopy, flexible; diagnostic, including collection of specimen(s)	<1%	1,234	$651K
93005	Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report	<1%	109,510	$650K
83735		<1%	167,436	$609K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	1,888	$605K
J0897	Injection, denosumab, 1 mg	<1%	1,673	$599K
95813		<1%	1,442	$595K
77387		<1%	17,600	$586K
96110	Developmental screening, with scoring and documentation, per standardized instrument	<1%	59,714	$576K
Q9991	Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg	<1%	881	$567K
90460	Immunization administration through 18 years of age via any route, first or only component	<1%	73,559	$565K
86481		<1%	9,852	$555K
90870		<1%	1,374	$550K
99381		<1%	4,159	$547K
97803		<1%	9,475	$544K
77300		<1%	3,625	$541K
J2469	Injection, palonosetron hcl, 25 mcg	<1%	5,680	$536K
93017		<1%	7,495	$535K
95811		<1%	724	$530K
95782		<1%	501	$530K
80048	Basic metabolic panel (calcium, ionized)	<1%	275,977	$527K
85027		<1%	146,713	$523K
ATP15		<1%	64,190	$523K
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine	<1%	69,539	$520K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	<1%	429	$508K
83880		<1%	25,185	$504K
73564		<1%	15,140	$502K
83036	Hemoglobin; glycosylated (A1C)	<1%	108,344	$500K
75574		<1%	3,200	$489K
76536		<1%	5,098	$483K
77295		<1%	1,333	$471K
87631		<1%	6,614	$468K
90686		<1%	69,810	$463K
84484		<1%	41,367	$459K
J7298	Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg	<1%	527	$456K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	27,773	$451K
J1950	Injection, leuprolide acetate (for depot suspension), per 3.75 mg	<1%	620	$440K
S0302	Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service)	<1%	53,447	$439K
90853	Group psychotherapy (other than of a multiple-family group)	<1%	16,596	$420K
88307		<1%	6,222	$420K
76882		<1%	4,170	$418K
87536		<1%	10,021	$415K
97116		<1%	10,638	$413K
ATP14		<1%	56,663	$406K
J9395	Injection, fulvestrant, 25 mg	<1%	857	$401K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	<1%	1,242	$399K
90791	Psychiatric diagnostic evaluation	<1%	4,388	$394K
29700		<1%	2,636	$381K
73610		<1%	13,507	$376K
G0105	Colorectal cancer screening; colonoscopy on individual at high risk	<1%	741	$371K
97162		<1%	11,676	$368K
72148	Magnetic resonance imaging, lumbar spine; without contrast material	<1%	2,804	$367K
0241U	Neonatal screening for hereditary disorders, genomic sequence analysis panel	<1%	11,394	$366K
J1453	Injection, fosaprepitant, 1 mg	<1%	1,014	$360K
71250		<1%	7,703	$359K
J9305	Injection, pemetrexed, not otherwise specified, 10 mg	<1%	254	$357K
73030		<1%	11,707	$355K
93505		<1%	595	$350K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	16,325	$344K
82728		<1%	46,588	$342K
ATP08		<1%	60,232	$342K
96416		<1%	2,762	$341K
J9310	Injection, rituximab, 100 mg	<1%	426	$331K
97165		<1%	4,065	$327K
88185		<1%	1,313	$327K
62323		<1%	858	$325K
70544		<1%	1,957	$322K
87086	Culture, bacterial; quantitative colony count, urine	<1%	64,239	$322K
94375		<1%	7,567	$322K
95886		<1%	1,665	$322K
J9306	Injection, pertuzumab, 1 mg	<1%	118	$321K
83605		<1%	34,440	$319K
96401		<1%	3,892	$319K
73630		<1%	14,396	$318K
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	<1%	16,429	$312K
72125	Computed tomography, cervical spine; without contrast material	<1%	8,010	$312K
80076		<1%	153,047	$311K
77301		<1%	997	$307K
20610		<1%	2,657	$297K
77067	Screening mammography, bilateral, including computer-aided detection	<1%	27,340	$296K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	9,883	$296K
97802		<1%	4,820	$295K
86850		<1%	43,504	$290K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	13,677	$289K
J1756	Injection, iron sucrose, 1 mg	<1%	4,256	$288K
93975		<1%	2,990	$284K
86780		<1%	28,487	$282K
90847	Family psychotherapy with the patient present, 50 minutes	<1%	3,167	$281K
70491		<1%	3,162	$280K
0001A		<1%	9,853	$280K
J7050	Infusion, normal saline solution, 250 cc	<1%	77,021	$277K
72141		<1%	1,596	$277K
72197		<1%	990	$275K
93303	Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study	<1%	1,115	$273K
73721	Magnetic resonance imaging, any joint of lower extremity; without contrast material	<1%	1,272	$271K
76942		<1%	4,500	$268K
Q5111	Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg	<1%	167	$264K
84702		<1%	20,200	$262K
90792	Psychiatric diagnostic evaluation with medical services	<1%	3,798	$262K
0002A		<1%	8,706	$260K
77062		<1%	3,074	$260K
J2704	Injection, propofol, 10 mg	<1%	52,549	$253K
81025		<1%	42,787	$253K
93325		<1%	3,618	$250K
J9999	Not otherwise classified, antineoplastic drugs	<1%	4,180	$249K
86803		<1%	29,166	$248K
90750		<1%	3,410	$248K
83970		<1%	14,212	$242K
J1200	Injection, diphenhydramine hcl, up to 50 mg	<1%	15,743	$242K
74018		<1%	5,982	$242K
58300		<1%	1,260	$239K
70498		<1%	3,585	$238K
82784		<1%	31,999	$236K
83690		<1%	47,398	$236K
J2405	Injection, ondansetron hydrochloride, per 1 mg	<1%	65,681	$231K
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	<1%	11,266	$230K
17110		<1%	1,454	$229K
82607		<1%	33,418	$229K
19083		<1%	313	$229K
97760		<1%	5,038	$227K
77290		<1%	886	$226K
73130		<1%	9,099	$220K
J0574	Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine	<1%	5,358	$217K
80053	Comprehensive metabolic panel	<1%	200,324	$213K
72170		<1%	5,114	$213K
73110		<1%	7,584	$210K
93976		<1%	1,990	$208K
J9070	Cyclophosphamide, 100 mg	<1%	1,506	$205K
87040		<1%	15,244	$205K
20553		<1%	1,636	$203K
87522	Neg quan hep c or qual rna	<1%	7,071	$201K
90715		<1%	14,518	$201K
80050	General health panel	<1%	13,874	$201K
83550		<1%	43,475	$200K
85610		<1%	89,148	$199K
74174		<1%	2,155	$198K
82803		<1%	12,228	$196K
96409		<1%	3,879	$195K
J1650	Injection, enoxaparin sodium, 10 mg	<1%	12,434	$192K
94640	Pressurized or nonpressurized inhalation treatment for acute airway obstruction	<1%	3,068	$190K
92523		<1%	1,592	$189K
77061		<1%	1,888	$186K
92552		<1%	1,866	$184K
99204	Doctor's office visit, new patient (more involved)	<1%	1,704	$183K
ATP16		<1%	23,620	$182K
70486		<1%	2,894	$182K
92611		<1%	2,016	$180K
76604		<1%	2,182	$180K
J1050	Injection, medroxyprogesterone acetate, 1 mg	<1%	4,305	$180K
96411		<1%	4,205	$178K
73502		<1%	7,772	$177K
72100		<1%	6,999	$175K
86480		<1%	3,673	$174K
76870		<1%	1,894	$173K
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	15,226	$173K
77065	Tomosynthesis, mammo	<1%	4,831	$171K
ATP17		<1%	24,171	$170K
86140		<1%	50,466	$164K
44970		<1%	50	$160K
93880		<1%	2,443	$157K
87070		<1%	26,591	$154K
87077		<1%	26,389	$154K
87497		<1%	8,348	$150K
88346		<1%	1,713	$149K
72082		<1%	2,623	$148K
29075		<1%	644	$148K
0124A		<1%	5,454	$147K
84403		<1%	10,325	$145K
77280		<1%	1,175	$144K
J9201	Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg	<1%	1,179	$143K
29705		<1%	802	$142K
95819		<1%	544	$142K
86360		<1%	7,087	$142K
J2796	Injection, romiplostim, 10 micrograms	<1%	328	$141K
87340		<1%	19,703	$140K
87186		<1%	23,392	$140K
96368		<1%	2,928	$132K
84439		<1%	24,049	$132K
88360		<1%	1,662	$131K
99385		<1%	2,171	$129K
Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg	<1%	1,251	$129K
90846	Family psychotherapy without the patient present, 50 minutes	<1%	1,355	$127K
96133		<1%	314	$127K
73560		<1%	5,496	$126K
95885		<1%	864	$126K
83516		<1%	11,614	$126K
92508	Group treatment of speech, language, voice, communication, and/or auditory processing disorder	<1%	1,282	$125K
88304		<1%	4,189	$124K
86359		<1%	7,713	$123K
41899	Unlisted procedure, dentoalveolar structures	<1%	140	$122K
10060		<1%	784	$121K
11981		<1%	584	$121K
0071A		<1%	2,761	$119K
11056		<1%	1,227	$119K
83540		<1%	35,704	$119K
88112		<1%	3,535	$118K
58301		<1%	644	$116K
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	36,924	$114K
73590		<1%	5,077	$113K
64721		<1%	151	$112K
81001		<1%	64,702	$111K
96118		<1%	184	$111K
86900		<1%	44,209	$110K
J9299	Injection, nivolumab, 1 mg	<1%	148	$109K
86923		<1%	4,982	$109K
74019		<1%	1,910	$108K
88342		<1%	8,963	$108K
J3010	Injection, fentanyl citrate, 0.1 mg	<1%	58,489	$107K
29881		<1%	63	$107K
90837	Psychotherapy session, about an hour	<1%	962	$106K
86706		<1%	15,074	$105K
86901		<1%	44,155	$104K
93923		<1%	2,023	$103K
77338		<1%	1,062	$103K
87081		<1%	17,759	$103K
86356		<1%	7,759	$101K
82746		<1%	14,506	$98K
87806		<1%	5,653	$98K
J0131	Injection, acetaminophen, not otherwise specified,10 mg	<1%	4,074	$97K
96402		<1%	3,636	$97K
76857		<1%	1,669	$96K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	2,249	$96K
73700		<1%	1,259	$95K
84153		<1%	11,296	$93K
85379		<1%	13,191	$92K
ATP03		<1%	32,758	$91K
97166		<1%	1,462	$90K
77002		<1%	1,483	$89K
58571		<1%	24	$88K
58100		<1%	423	$88K
88341		<1%	3,809	$88K
J2250	Injection, midazolam hydrochloride, per 1 mg	<1%	46,273	$87K
73140		<1%	3,199	$87K
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	31,277	$86K
72040		<1%	2,561	$86K
P9016	Red blood cells, leukocytes reduced, each unit	<1%	3,441	$86K
85730		<1%	20,177	$86K
86235		<1%	2,913	$86K
J1170	Injection, hydromorphone, up to 4 mg	<1%	24,418	$85K
84146		<1%	7,376	$85K
74178		<1%	572	$85K
94060		<1%	1,775	$84K
99495		<1%	1,030	$84K
99173		<1%	2,666	$84K
J1644	Injection, heparin sodium, per 1000 units	<1%	11,639	$81K
76815	Ultrasound, pregnant uterus, real time with image documentation, limited	<1%	1,602	$80K
85652		<1%	49,463	$79K
90677		<1%	3,677	$79K
87799		<1%	5,729	$79K
73562		<1%	2,733	$79K
80197		<1%	18,153	$77K
82570		<1%	35,528	$76K
J3489	Injection, zoledronic acid, 1 mg	<1%	2,640	$76K
83883		<1%	8,525	$76K
82670		<1%	4,432	$76K
82378		<1%	10,069	$75K
80061	Lipid panel	<1%	102,516	$74K
90461		<1%	23,465	$74K
96523		<1%	2,226	$74K
90696		<1%	4,183	$74K
83001		<1%	6,380	$74K
12011		<1%	394	$74K
J0690	Injection, cefazolin sodium, 500 mg	<1%	24,202	$72K
ATP07		<1%	12,002	$72K
90935	Hemodialysis procedure with single evaluation by a physician	<1%	279	$71K
99496		<1%	767	$71K
73090		<1%	3,096	$71K
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	<1%	64,848	$70K
73080		<1%	3,132	$70K
86003		<1%	2,232	$70K
77066	Tomosynthesis, mammo	<1%	4,711	$69K
84100		<1%	91,560	$69K
77332		<1%	767	$68K
72156		<1%	432	$67K
86704		<1%	8,933	$67K
ATP09		<1%	12,550	$67K
73060		<1%	2,065	$67K
85007		<1%	30,868	$66K
12001		<1%	392	$66K
88173		<1%	1,399	$65K
73552		<1%	3,294	$65K
81003		<1%	47,613	$65K
96417		<1%	8,973	$64K
93797		<1%	1,514	$64K
0054A		<1%	3,118	$64K
J2543	Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams)	<1%	2,733	$64K
0072A		<1%	1,416	$64K
ATP18		<1%	9,114	$63K
ATP10		<1%	11,377	$63K
94729		<1%	3,930	$63K
87641		<1%	2,756	$63K
90691		<1%	2,682	$63K
96376		<1%	14,712	$62K
73221		<1%	295	$62K
0004A		<1%	2,315	$61K
82105		<1%	7,227	$61K
86038		<1%	8,835	$61K
ATP11		<1%	10,864	$61K
87517		<1%	3,040	$61K
36561		<1%	82	$60K
Q0139	Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis)	<1%	224	$58K
83002		<1%	4,881	$58K
G0297	Low dose ct scan (ldct) for lung cancer screening	<1%	622	$57K
99386		<1%	1,134	$57K
90746		<1%	3,114	$57K
11055		<1%	567	$56K
82043		<1%	27,080	$56K
86832		<1%	425	$56K
J0248	Injection, remdesivir, 1 mg	<1%	157	$55K
J0585	Injection, onabotulinumtoxina, 1 unit	<1%	88	$55K
92526		<1%	616	$55K
51705		<1%	510	$54K
77470		<1%	203	$53K
86787		<1%	5,616	$53K
77049		<1%	181	$53K
76937		<1%	2,576	$52K
99383		<1%	617	$52K
87205		<1%	17,889	$51K
84165		<1%	13,814	$51K
87902		<1%	457	$50K
85013		<1%	12,695	$50K
73070		<1%	1,386	$50K
77385		<1%	305	$50K
11982		<1%	287	$49K
46607		<1%	76	$49K
99188		<1%	3,083	$48K
J2060	Injection, lorazepam, 2 mg	<1%	11,869	$48K
G0108	Diabetes outpatient self-management training services, individual, per 30 minutes	<1%	1,385	$47K
86765		<1%	5,305	$47K
88313		<1%	2,019	$47K
J3475	Injection, magnesium sulfate, per 500 mg	<1%	17,938	$46K
84480		<1%	5,985	$45K
29065		<1%	173	$45K
87338		<1%	4,754	$45K
83520		<1%	4,622	$45K
99443		<1%	6,435	$45K
87400		<1%	2,365	$45K
71271		<1%	1,600	$45K
82330		<1%	5,373	$45K
90714		<1%	2,340	$44K
90732		<1%	3,336	$44K
86160		<1%	3,462	$44K
90480		<1%	3,528	$44K
J1944	Injection, aripiprazole lauroxil, (aristada), 1 mg	<1%	40	$43K
86039		<1%	6,570	$43K
84270		<1%	3,184	$43K
87625		<1%	2,670	$43K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	1,681	$42K
90833	Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on)	<1%	2,134	$42K
94726		<1%	1,633	$41K
C1769	Guide wire	<1%	6,622	$41K
86147		<1%	1,766	$41K
86665		<1%	1,912	$40K
95816		<1%	189	$40K
96137		<1%	197	$40K
G0279	Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066)	<1%	2,682	$39K
86762		<1%	3,473	$39K
88184		<1%	1,420	$38K
90472	Immunization administration, each additional vaccine (list separately)	<1%	16,332	$38K
64493		<1%	82	$38K
86355		<1%	2,367	$38K
91010		<1%	55	$38K
86708		<1%	4,584	$38K
90662		<1%	10,846	$37K
87209		<1%	3,277	$37K
J7120	Ringers lactate infusion, up to 1000 cc	<1%	17,080	$37K
77072		<1%	1,278	$36K
S0020	Injection, bupivicaine hydrochloride, 30 ml	<1%	1,509	$35K
73523		<1%	815	$35K
82533		<1%	4,234	$35K
11719		<1%	2,417	$35K
87102		<1%	6,451	$34K
47000		<1%	117	$34K
J2930	Injection, methylprednisolone sodium succinate, up to 125 mg	<1%	4,318	$34K
96132		<1%	328	$34K
86833		<1%	300	$34K
72158		<1%	356	$34K
72070		<1%	1,278	$33K
J0696	Injection, ceftriaxone sodium, per 250 mg	<1%	11,142	$33K
0051A		<1%	843	$33K
83020		<1%	2,981	$33K
78306		<1%	244	$33K
87808		<1%	3,553	$33K
93321		<1%	738	$32K
J0834	Injection, cosyntropin, 0.25 mg	<1%	508	$32K
91322		<1%	1,677	$31K
ATP23		<1%	3,422	$31K
82785		<1%	2,755	$31K
20680		<1%	27	$31K
J9145	Injection, daratumumab, 10 mg	<1%	47	$31K
27447		<1%	12	$30K
83615		<1%	40,105	$30K
86618		<1%	3,080	$30K
96116		<1%	227	$30K
36902		<1%	33	$30K
70548		<1%	361	$29K
85045		<1%	14,468	$29K
0081A		<1%	682	$29K
99397		<1%	890	$29K
Q3014	Telehealth originating site facility fee	<1%	19,237	$29K
93320		<1%	1,566	$29K
49083		<1%	83	$29K
86677		<1%	2,934	$28K
84425		<1%	2,528	$28K
93225		<1%	737	$28K
19301		<1%	28	$28K
86141		<1%	4,276	$27K
86301		<1%	2,735	$27K
82550		<1%	15,320	$27K
54161		<1%	12	$26K
99382		<1%	332	$26K
82627		<1%	1,620	$26K
76817	Ultrasound, pregnant uterus, real time with image documentation, transvaginal	<1%	731	$26K
82232		<1%	6,002	$26K
77001		<1%	478	$25K
90670		<1%	17,337	$25K
A9575	Injection, gadoterate meglumine, 0.1 ml	<1%	18,401	$25K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	<1%	192	$25K
86334		<1%	3,483	$25K
84156		<1%	15,412	$25K
J2997	Injection, alteplase recombinant, 1 mg	<1%	343	$25K
73100		<1%	620	$25K
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	<1%	8,278	$24K
36415	Collection of venous blood by venipuncture	<1%	169,422	$24K
J3370	Injection, vancomycin hcl, 500 mg	<1%	6,477	$24K
J1630	Injection, haloperidol, up to 5 mg	<1%	14,156	$24K
84305		<1%	2,045	$24K
96139		<1%	145	$23K
86225		<1%	3,105	$23K
81002		<1%	11,252	$23K
95913		<1%	335	$23K
86300		<1%	3,378	$23K
J2001	Injection, lidocaine hcl for intravenous infusion, 10 mg	<1%	42,333	$23K
86304		<1%	2,641	$22K
87640		<1%	2,206	$22K
0082A		<1%	489	$22K
82140		<1%	2,493	$21K
80164		<1%	3,582	$21K
70355		<1%	1,008	$21K
82947		<1%	11,309	$21K
93926		<1%	91	$21K
C1894	Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser	<1%	4,585	$21K
0154A		<1%	591	$20K
80299		<1%	2,129	$20K
77059		<1%	14	$20K
72081		<1%	246	$20K
87116		<1%	2,976	$20K
C1887	Catheter, guiding (may include infusion/perfusion capability)	<1%	2,629	$20K
86255		<1%	2,075	$20K
72110		<1%	608	$20K
83993		<1%	1,524	$19K
86727		<1%	2,246	$19K
J0171	Injection, adrenalin, epinephrine, 0.1 mg	<1%	2,835	$19K
99384		<1%	293	$19K
G0127	Trimming of dystrophic nails, any number	<1%	5,255	$19K
86709		<1%	2,593	$19K
86735		<1%	2,407	$19K
G0439	Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit	<1%	5,796	$19K
86769		<1%	763	$19K
86376		<1%	1,976	$19K
86200		<1%	2,845	$19K
M0243	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring	<1%	66	$18K
87177		<1%	3,301	$18K
87206		<1%	4,266	$18K
J9041	Injection, bortezomib, 0.1 mg	<1%	201	$18K
82610		<1%	3,252	$18K
74246		<1%	120	$18K
88312		<1%	1,523	$18K
87045		<1%	3,172	$18K
J7030	Infusion, normal saline solution , 1000 cc	<1%	4,581	$18K
85240		<1%	1,337	$18K
87046		<1%	3,158	$18K
83010		<1%	2,756	$18K
58661		<1%	12	$18K
J2270	Injection, morphine sulfate, up to 10 mg	<1%	14,001	$18K
72050		<1%	509	$17K
83021		<1%	1,165	$17K
G0498	Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion	<1%	714	$17K
82088		<1%	771	$17K
90632		<1%	771	$17K
87529		<1%	739	$17K
90836		<1%	1,269	$17K
J2795	Injection, ropivacaine hydrochloride, 1 mg	<1%	6,252	$17K
95910		<1%	180	$16K
86800		<1%	2,037	$16K
76376		<1%	226	$16K
94727		<1%	721	$16K
77077		<1%	490	$16K
85384		<1%	3,175	$16K
64483		<1%	28	$16K
93924		<1%	176	$16K
ATP04		<1%	2,845	$16K
83498		<1%	737	$16K
86146		<1%	1,146	$16K
73200		<1%	334	$15K
93454		<1%	12	$15K
87486		<1%	550	$15K
87581		<1%	549	$15K
86945		<1%	1,722	$15K
J0692	Injection, cefepime hydrochloride, 500 mg	<1%	2,897	$15K
19081		<1%	26	$15K
90734		<1%	7,211	$15K
Q0162	Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	<1%	9,290	$15K
91320		<1%	762	$15K
82150		<1%	3,940	$15K
85246		<1%	831	$15K
G0008	Administration of influenza virus vaccine	<1%	14,951	$15K
86664		<1%	1,307	$15K
73000		<1%	414	$14K
75561		<1%	66	$14K
87811	Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19)	<1%	522	$14K
96136		<1%	291	$14K
J1447	Injection, tbo-filgrastim, 1 microgram	<1%	59	$14K
J9171	Injection, docetaxel, 1 mg	<1%	79	$14K
87184		<1%	2,765	$14K
87269		<1%	1,815	$14K
87272		<1%	1,815	$14K
82010		<1%	2,186	$14K
89051		<1%	3,328	$14K
76981		<1%	164	$14K
J2370	Injection, phenylephrine hcl, up to 1 ml	<1%	13,072	$14K
J7060	5% dextrose/water (500 ml = 1 unit)	<1%	11,570	$14K
78264		<1%	54	$14K
91200		<1%	328	$14K
0074A		<1%	346	$13K
87324		<1%	2,161	$13K
85245		<1%	717	$13K
86325		<1%	1,635	$13K
86580		<1%	1,826	$13K
76775		<1%	251	$13K
86431		<1%	4,423	$13K
29540		<1%	180	$13K
0011A		<1%	426	$13K
83525		<1%	1,882	$13K
82024		<1%	614	$13K
J1720	Injection, hydrocortisone sodium succinate, up to 100 mg	<1%	2,052	$13K
11042	Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm	<1%	116	$13K
0031A		<1%	366	$13K
80177		<1%	1,739	$12K
83521		<1%	5,867	$12K
J0780	Injection, prochlorperazine, up to 10 mg	<1%	1,619	$12K
83921		<1%	1,514	$12K
86644		<1%	1,217	$12K
90620		<1%	168	$12K
86357		<1%	830	$12K
84432		<1%	1,522	$12K
80175		<1%	1,812	$12K
72146		<1%	171	$12K
J0640	Injection, leucovorin calcium, per 50 mg	<1%	3,205	$12K
71101		<1%	785	$12K
84445		<1%	329	$12K
J0561	Injection, penicillin g benzathine, 100,000 units	<1%	111	$12K
99218		<1%	109	$12K
ATP02		<1%	3,007	$11K
J2426	Injection, paliperidone palmitate extended release (invega sustenna), 1 mg	<1%	18	$11K
93226		<1%	521	$11K
82248		<1%	18,015	$11K
ATP19		<1%	1,651	$11K
12002		<1%	65	$11K
J7999	Compounded drug, not otherwise classified	<1%	2,502	$11K
ATP05		<1%	1,692	$11K
72157		<1%	194	$11K
86021		<1%	1,156	$11K
87106		<1%	1,436	$10K
87329		<1%	1,462	$10K
ATP13		<1%	1,409	$10K
84244		<1%	845	$10K
C7900	Service for diagnosis, evaluation, or treatment of a mental health or substance use disorder, 15-29 minutes, provided remotely by hospital staff who are licensed to provide mental health services under applicable state law(s), when the patient is in their home, and there is no associated professional service	<1%	1,368	$10K
36589		<1%	55	$10K
87075		<1%	1,334	$10K
J9045	Injection, carboplatin, 50 mg	<1%	2,318	$9K
80069		<1%	12,078	$9K
80400		<1%	614	$9K
82274		<1%	1,165	$9K
78431		<1%	30	$9K
86870		<1%	671	$9K
38525		<1%	13	$9K
29125		<1%	78	$9K
93246		<1%	1,808	$9K
86317		<1%	218	$9K
81228		<1%	13	$9K
90656		<1%	1,231	$9K
94760		<1%	5,701	$9K
82787		<1%	622	$9K
84132		<1%	6,368	$9K
83519		<1%	980	$8K
74221		<1%	68	$8K
0012A		<1%	255	$8K
29425		<1%	35	$8K
73701		<1%	69	$8K
90707		<1%	5,029	$8K
95923		<1%	25	$8K
84154		<1%	1,445	$8K
80178		<1%	2,888	$8K
74220		<1%	146	$8K
87252		<1%	422	$8K
73660		<1%	501	$8K
84550		<1%	14,417	$8K
J2920	Injection, methylprednisolone sodium succinate, up to 40 mg	<1%	2,420	$8K
J0295	Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm	<1%	1,897	$7K
27096		<1%	12	$7K
90716		<1%	4,604	$7K
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	5,323	$7K
69210		<1%	446	$7K
J0689	Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg	<1%	888	$7K
86592		<1%	2,578	$7K
83090		<1%	800	$7K
97763		<1%	423	$7K
99417	Prolong home eval add 15m	<1%	242	$7K
0052A		<1%	160	$7K
84207		<1%	503	$7K
88262		<1%	79	$7K
88142		<1%	522	$7K
99442		<1%	1,374	$7K
J9000	Injection, doxorubicin hydrochloride, 10 mg	<1%	751	$6K
87299		<1%	933	$6K
87210		<1%	2,006	$6K
17000		<1%	51	$6K
29405		<1%	27	$6K
77370		<1%	170	$6K
73120		<1%	632	$6K
J0134	Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg	<1%	2,388	$6K
31575		<1%	40	$6K
84630		<1%	730	$6K
69209		<1%	99	$6K
83930		<1%	1,655	$6K
11100		<1%	25	$6K
82962		<1%	22,744	$6K
A9552	Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries	<1%	3,329	$6K
20550		<1%	24	$6K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	328	$6K
82390		<1%	800	$6K
P9021	Red blood cells, each unit	<1%	478	$5K
M0245	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring	<1%	24	$5K
82103		<1%	646	$5K
82810		<1%	1,139	$5K
0003A		<1%	236	$5K
M0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring	<1%	123	$5K
77012		<1%	271	$5K
0064A		<1%	221	$5K
95812		<1%	13	$5K
J9206	Injection, irinotecan, 20 mg	<1%	1,251	$5K
85520		<1%	677	$5K
84295		<1%	4,165	$5K
36410		<1%	4,519	$5K
97533		<1%	28	$5K
73503		<1%	168	$5K
C1751	Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis)	<1%	364	$5K
11720		<1%	447	$5K
82172		<1%	371	$5K
J7040	Infusion, normal saline solution, sterile (500 ml = 1 unit)	<1%	3,391	$5K
80202		<1%	677	$5K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	170	$5K
J1642	Injection, heparin sodium, (heparin lock flush), per 10 units	<1%	194	$5K
86705		<1%	688	$5K
Q0222	Injection, bebtelovimab, 175 mg	<1%	92	$5K
82977		<1%	4,869	$5K
77523		<1%	124	$5K
G8978	Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals	<1%	1,823	$5K
88365		<1%	56	$5K
38222		<1%	16	$5K
88381		<1%	100	$5K
96138		<1%	167	$5K
J8540	Dexamethasone, oral, 0.25 mg	<1%	16,504	$5K
99153	Mod sedat endo service >5yrs	<1%	9,194	$5K
62270		<1%	15	$5K
C7901	Service for diagnosis, evaluation, or treatment of a mental health or substance use disorder, 30-60 minutes, provided remotely by hospital staff who are licensed to provided mental health services under applicable state law(s), when the patient is in their home, and there is no associated professional service	<1%	3,225	$5K
84590		<1%	753	$4K
84300		<1%	1,883	$4K
77307		<1%	31	$4K
0296T		<1%	1,670	$4K
87274		<1%	568	$4K
87290		<1%	567	$4K
83835		<1%	394	$4K
10061		<1%	42	$4K
0083A		<1%	90	$4K
80143		<1%	565	$4K
83935		<1%	1,239	$4K
80179		<1%	472	$4K
82565		<1%	6,394	$4K
20552		<1%	29	$4K
85307		<1%	413	$4K
11976		<1%	13	$4K
80195		<1%	806	$4K
0173A		<1%	109	$4K
11721		<1%	248	$4K
A9500	Technetium tc-99m sestamibi, diagnostic, per study dose	<1%	4,508	$3K
88311		<1%	828	$3K
85300		<1%	453	$3K
83789		<1%	354	$3K
20605		<1%	27	$3K
81240		<1%	164	$3K
74175		<1%	149	$3K
82310		<1%	4,472	$3K
85303		<1%	353	$3K
75572		<1%	54	$3K
87563		<1%	165	$3K
J0461	Injection, atropine sulfate, 0.01 mg	<1%	1,279	$3K
86703		<1%	307	$3K
85305		<1%	372	$3K
J0694	Injection, cefoxitin sodium, 1 gm	<1%	126	$3K
M0247	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring	<1%	84	$3K
82945		<1%	1,323	$3K
90474		<1%	2,351	$3K
58340		<1%	13	$3K
86341		<1%	203	$3K
84134		<1%	351	$3K
84402		<1%	181	$3K
ATP12		<1%	478	$2K
80156		<1%	388	$2K
70543		<1%	12	$2K
M0222	Intravenous injection, bebtelovimab, includes injection and post administration monitoring	<1%	17	$2K
91120		<1%	13	$2K
70487		<1%	25	$2K
84466		<1%	326	$2K
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	2,723	$2K
82657		<1%	174	$2K
76706		<1%	90	$2K
J0137	Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg	<1%	1,352	$2K
P9035	Platelets, pheresis, leukocytes reduced, each unit	<1%	117	$2K
87807		<1%	210	$2K
82180		<1%	293	$2K
88331		<1%	191	$2K
82085		<1%	470	$2K
94010		<1%	72	$2K
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established)	<1%	901	$2K
J3360	Injection, diazepam, up to 5 mg	<1%	572	$2K
96377		<1%	650	$2K
72190		<1%	62	$2K
93798		<1%	68	$2K
96111		<1%	45	$2K
84681		<1%	162	$2K
85018		<1%	1,925	$2K
J3590	Unclassified biologics	<1%	116	$2K
82668		<1%	258	$2K
G0009	Administration of pneumococcal vaccine	<1%	3,434	$2K
J9190	Injection, fluorouracil, 500 mg	<1%	6,679	$2K
95924		<1%	24	$2K
72131		<1%	156	$2K
87505		<1%	35	$2K
J7300	Intrauterine copper contraceptive (paragard)	<1%	12	$2K
J0665	Injection, bupivicaine, not otherwise specified, 0.5 mg	<1%	1,661	$2K
99195		<1%	29	$2K
83695		<1%	261	$1K
0134A		<1%	64	$1K
Q0091	Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory	<1%	12,362	$1K
76098		<1%	68	$1K
88368		<1%	40	$1K
93350		<1%	27	$1K
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	<1%	1,998	$1K
84155		<1%	3,195	$1K
99493		<1%	70	$1K
J2785	Injection, regadenoson, 0.1 mg	<1%	2,539	$1K
84144		<1%	91	$1K
82379		<1%	177	$1K
J9267	Injection, paclitaxel, 1 mg	<1%	2,941	$1K
J2272	Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg	<1%	709	$1K
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	214	$1K
S0028	Injection, famotidine, 20 mg	<1%	192	$1K
J9370	Vincristine sulfate, 1 mg	<1%	940	$1K
93242		<1%	290	$1K
91122		<1%	16	$1K
Q9966	Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml	<1%	2,613	$1K
J3411	Injection, thiamine hcl, 100 mg	<1%	443	$1K
86308		<1%	278	$1K
J1836	Injection, metronidazole, 10 mg	<1%	448	$1K
82270		<1%	408	$1K
ATP06		<1%	182	$1K
J2765	Injection, metoclopramide hcl, up to 10 mg	<1%	7,006	$1K
86707		<1%	169	$1K
85014		<1%	497	$1K
95911		<1%	24	$1K
88172		<1%	75	$963.51
80230		<1%	55	$938.70
82465		<1%	922	$938.48
G0257	Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility	<1%	665	$914.14
84080		<1%	148	$881.32
82652		<1%	44	$852.34
94761		<1%	1,446	$845.39
86696		<1%	56	$840.60
J1580	Injection, garamycin, gentamicin, up to 80 mg	<1%	328	$827.03
0073A		<1%	17	$779.79
84520		<1%	5,030	$779.57
82247		<1%	3,248	$773.11
87901		<1%	14	$763.56
J2175	Injection, meperidine hydrochloride, per 100 mg	<1%	939	$762.12
89060		<1%	238	$744.22
J7507	Tacrolimus, immediate release, oral, 1 mg	<1%	183	$741.33
82139		<1%	69	$734.54
J2400	Injection, chloroprocaine hydrochloride, per 30 ml	<1%	13	$712.70
J0330	Injection, succinylcholine chloride, up to 20 mg	<1%	6,759	$695.57
84460		<1%	6,634	$675.20
87260		<1%	383	$673.17
87279		<1%	385	$673.17
99152		<1%	8,565	$669.68
S0119	Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code)	<1%	9,846	$666.78
82365		<1%	78	$661.55
G0270	Medical nutrition therapy; reassessment and subsequent intervention(s) following second referral in same year for change in diagnosis, medical condition or treatment regimen (including additional hours needed for renal disease), individual, face to face with the patient, each 15 minutes	<1%	53	$653.64
72220		<1%	39	$643.62
90473		<1%	21	$639.37
J1596	Injection, glycopyrrolate, 0.1 mg	<1%	55	$635.56
82985		<1%	107	$627.66
87350		<1%	109	$622.70
84145		<1%	496	$611.00
86256		<1%	84	$609.07
0111A		<1%	13	$596.31
Q9969	Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose	<1%	1,395	$582.60
86695		<1%	56	$572.64
97164		<1%	29	$563.23
72202		<1%	28	$554.10
M0223	Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	<1%	12	$550.50
90633		<1%	10,299	$545.32
J2710	Injection, neostigmine methylsulfate, up to 0.5 mg	<1%	2,855	$519.81
86008		<1%	281	$510.73
93041		<1%	868	$507.88
86880		<1%	201	$502.14
82525		<1%	52	$482.32
84450		<1%	5,780	$482.31
93010	Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only	<1%	101	$475.29
G0500	Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate)	<1%	5,165	$453.12
84235		<1%	14	$431.68
73600		<1%	33	$428.43
99202	Office or other outpatient visit for the evaluation and management of a new patient, straightforward	<1%	13	$424.38
75635		<1%	14	$423.70
87427		<1%	57	$413.35
84446		<1%	55	$410.63
90621		<1%	27	$409.86
99494		<1%	63	$398.53
90688		<1%	694	$393.24
86645		<1%	30	$382.72
85613		<1%	84	$379.13
73620		<1%	57	$376.95
0053A		<1%	14	$366.96
C1729	Catheter, drainage	<1%	273	$354.76
82164		<1%	44	$331.12
G8979	Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	<1%	1,882	$323.53
H0046	Mental health services, not otherwise specified	<1%	15	$322.20
0034A		<1%	16	$321.09
90682		<1%	17	$320.23
J0688	Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg	<1%	458	$312.91
82040		<1%	2,182	$307.57
L4386	Walking boot, non-pneumatic, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise	<1%	1,554	$302.36
86682		<1%	29	$292.75
85306		<1%	32	$279.68
J3371	Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg	<1%	291	$278.05
82166		<1%	24	$272.48
86777		<1%	28	$258.20
99492		<1%	15	$256.01
82542		<1%	14	$255.00
C1725	Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability)	<1%	903	$252.29
83718		<1%	39	$251.28
97163		<1%	17	$250.51
0121A		<1%	112	$242.11
87899		<1%	29	$236.98
G0438	Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit	<1%	196	$233.06
82955		<1%	38	$231.12
82239		<1%	15	$229.58
J0670	Injection, mepivacaine hydrochloride, per 10 ml	<1%	605	$227.66
80169		<1%	69	$225.60
87181		<1%	70	$217.09
90713		<1%	379	$211.95
80183		<1%	26	$205.53
73650		<1%	13	$188.52
J7510	Prednisolone oral, per 5 mg	<1%	337	$184.29
84075		<1%	1,855	$174.06
J1171	Injection, hydromorphone, 0.1 mg	<1%	317	$173.71
83986		<1%	68	$170.46
J2919	Injection, methylprednisolone sodium succinate, 5 mg	<1%	444	$165.50
87207		<1%	49	$163.57
J1790	Injection, droperidol, up to 5 mg	<1%	262	$162.06
80159		<1%	25	$159.93
87339		<1%	21	$153.53
87341		<1%	28	$150.72
84481		<1%	14	$139.76
J1805	Injection, esmolol hydrochloride, 10 mg	<1%	199	$138.70
80158		<1%	25	$131.68
36416		<1%	12,036	$128.09
95992		<1%	54	$116.08
84436		<1%	90	$115.50
A9541	Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries	<1%	625	$111.63
G0444	Annual depression screening, 5 to 15 minutes	<1%	212	$108.62
84133		<1%	44	$105.61
80185		<1%	24	$101.46
J2540	Injection, penicillin g potassium, up to 600,000 units	<1%	20	$97.30
80201		<1%	15	$94.59
90710		<1%	4,240	$91.88
82272		<1%	39	$91.71
93356		<1%	84	$88.36
87305		<1%	14	$84.56
G0442	Annual alcohol misuse screening, 5 to 15 minutes	<1%	144	$73.53
86036		<1%	433	$66.81
Q9950	Injection, sulfur hexafluoride lipid microspheres, per ml	<1%	222	$56.73
86316		<1%	13	$55.05
96040		<1%	521	$44.03
84478		<1%	286	$31.26
99441		<1%	17	$30.68
J3480	Injection, potassium chloride, per 2 meq	<1%	838	$28.27
J1815	Injection, insulin, per 5 units	<1%	21	$27.02
80348		<1%	2,646	$26.90
L3808	Wrist hand finger orthosis, rigid without joints, may include soft interface material; straps, custom fabricated, includes fitting and adjustment	<1%	409	$24.31
86037		<1%	108	$22.27
00731		<1%	12	$18.53
A9503	Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries	<1%	333	$18.06
J1920	Injection, labetalol hydrochloride, 5 mg	<1%	170	$16.03
J0280	Injection, aminophyllin, up to 250 mg	<1%	32	$11.39
G0145	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision	<1%	1,293	$6.48
J0744	Injection, ciprofloxacin for intravenous infusion, 200 mg	<1%	202	$4.80
96125		<1%	79	$4.63
C9113	Injection, pantoprazole sodium, per vial	<1%	605	$3.76
J3420	Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg	<1%	3,289	$2.46
J1940	Injection, furosemide, up to 20 mg	<1%	2,210	$1.28
Q0163	Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen	<1%	2,835	$1.05
J2003	Injection, lidocaine hydrochloride, 1 mg	<1%	39	$0.32
90749		<1%	396	$0.10
G1004	Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program	<1%	6,875	$0.01
90648		0%	13,127	$0.00
L3010	Foot, insert, removable, molded to patient model, longitudinal arch support, each	0%	306	$0.00
L3908	Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf	0%	871	$0.00
91300		0%	14,642	$0.00
J0735	Injection, clonidine hydrochloride, 1 mg	0%	174	$0.00
J9060	Injection, cisplatin, powder or solution, 10 mg	0%	499	$0.00
C1713	Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	0%	863	$0.00
80356		0%	2,646	$0.00
76821		0%	127	$0.00
90685		0%	745	$0.00
J1956	Injection, levofloxacin, 250 mg	0%	13	$0.00
L3913	Hand finger orthosis, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment	0%	458	$0.00
90700		0%	4,079	$0.00
L3807	Wrist hand finger orthosis, without joint(s), prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise	0%	352	$0.00
J1953	Injection, levetiracetam, 10 mg	0%	179	$0.00
J2720	Injection, protamine sulfate, per 10 mg	0%	26	$0.00
G8984	Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals	0%	424	$0.00
G0101	Cervical or vaginal cancer screening; pelvic and clinical breast examination	0%	14	$0.00
C1758	Catheter, ureteral	0%	12	$0.00
80364		0%	2,645	$0.00
G8997	Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	0%	71	$0.00
91312		0%	1,352	$0.00
C1760	Closure device, vascular (implantable/insertable)	0%	53	$0.00
G8985	Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	0%	438	$0.00
80365		0%	2,639	$0.00
78434		0%	30	$0.00
80346		0%	2,673	$0.00
76827		0%	124	$0.00
G8996	Swallowing functional limitation, current status at therapy episode outset and at reporting intervals	0%	71	$0.00
Q9957	Injection, perflutren lipid microspheres, per ml	0%	97	$0.00
51702		0%	90	$0.00
J0736	Injection, clindamycin phosphate, 300 mg	0%	20	$0.00
51701		0%	27	$0.00
J0153	Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds)	0%	134	$0.00
P9045	Infusion, albumin (human), 5%, 250 ml	0%	13	$0.00
G8989	Self care functional limitation, discharge status, at discharge from therapy or to end reporting	0%	32	$0.00
L1832	Knee orthosis, adjustable knee joints (unicentric or polycentric), positional orthosis, rigid support, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise	0%	25	$0.00
99401		0%	12	$0.00
C8929	Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography	0%	13	$0.00
82653		0%	12	$0.00
U0001	Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel	0%	45	$0.00
90672		0%	24	$0.00
M0248	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	0%	15	$0.00
J2359	Injection, olanzapine, 0.5 mg	0%	26	$0.00
0151A		0%	12	$0.00
96113		0%	13	$0.00
90680		0%	11,322	$0.00
76820		0%	128	$0.00
J0360	Injection, hydralazine hcl, up to 20 mg	0%	674	$0.00
G8982	Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	0%	150	$0.00
90697		0%	2,358	$0.00
90698		0%	270	$0.00
L4350	Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf	0%	432	$0.00
76825		0%	123	$0.00
87493		0%	278	$0.00
Q0164	Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	0%	482	$0.00
G0010	Administration of hepatitis b vaccine	0%	109	$0.00
Q0221	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg	0%	12	$0.00
L3906	Wrist hand orthosis, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment	0%	27	$0.00
80329		0%	276	$0.00
G8987	Self care functional limitation, current status, at therapy episode outset and at reporting intervals	0%	245	$0.00
36591		0%	291	$0.00
90723		0%	9,034	$0.00
80320		0%	1,188	$0.00
G8988	Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	0%	251	$0.00
90744		0%	1,511	$0.00
J0610	Injection, calcium gluconate (fresenius kabi), per 10 ml	0%	314	$0.00
86381		0%	240	$0.00
96112		0%	216	$0.00
80327		0%	28	$0.00
L3923	Hand finger orthosis, without joints, may include soft interface, straps, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise	0%	219	$0.00
91301		0%	479	$0.00
C1889	Implantable/insertable device, not otherwise classified	0%	82	$0.00
J2470	Injection, pantoprazole sodium, 40 mg	0%	59	$0.00
80353		0%	2,645	$0.00
G8986	Carrying, moving & handling objects functional limitation, discharge status, at discharge from therapy or to end reporting	0%	194	$0.00
C1819	Surgical tissue localization and excision device (implantable)	0%	13	$0.00
G8980	Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting	0%	678	$0.00
80358		0%	2,646	$0.00
L8030	Breast prosthesis, silicone or equal, without integral adhesive	0%	13	$0.00
A9540	Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries	0%	14	$0.00
J7613	Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg	0%	141	$0.00
A9555	Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries	0%	42	$0.00
G0123	Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision	0%	31	$0.00
J2305	Injection, nitroglycerin, 5 mg	0%	42	$0.00
J0611	Injection, calcium gluconate (wg critical care), per 10 ml	0%	14	$0.00
G8981	Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals	0%	142	$0.00
91303		0%	300	$0.00
80324		0%	2,645	$0.00
L4360	Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise	0%	135	$0.00
L3933	Finger orthosis, without joints, may include soft interface, custom fabricated, includes fitting and adjustment	0%	50	$0.00
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	0%	42	$0.00
J0456	Injection, azithromycin, 500 mg	0%	12	$0.00
A9585	Injection, gadobutrol, 0.1 ml	0%	24	$0.00
G8998	Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting	0%	13	$0.00
91307		0%	33	$0.00
82435		0%	28	$0.00
L4205	Repair of orthotic device, labor component, per 15 minutes	0%	16	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialBOEMER, SALLY (EVP)